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Abstract 
Introduction: N-methyl-D-aspartate receptor subunits antibody (NR2-ab) is a sensitive marker of ischemic brain 
damage in clinical circumstances, such as cerebrovascular accidents. We aimed to assess the value of serum NR2-
ab in predicting the post-cardiopulmonary resuscitation (CPR) survival. Methods: In this cohort study, we exam-
ined serum NR2-ab levels 1 hour after the return of spontaneous circulation (ROSC) in 49 successfully resuscitated 
patients. Patients with traumatic or asphyxic arrests, prior neurological insults, or major medical illnesses were 
excluded. Participants were followed until death or hospital discharge. Demographic data, coronary artery disease 
risk factors, time before initiation of CPR, and CPR duration were documented.  In addition, Glasgow coma scale 
(GCS), blood pressure, and survival status of patients were recorded at 1, 6, 24, and 72 hour(s) after ROSC. Descrip-
tive analyses were performed, and the Cox proportional hazard model was applied to assess if NR2-ab level is an 
independent predictive factor of survival. Results: 49 successfully resuscitated patients were evaluated; 27 (55%) 
survived to hospital discharge, 4 (8.1%) were in vegetative state, 10 (20.4%) were physically disabled, and 13 
(26.5%) were physically functional. Within 72 hours of ROSC all of the 12 NR2-ab positive patients died. In contrast, 
31 (84%) of the NR2-ab negative patients survived. Sensitivity, specificity, positive and negative likelihood ratios 
of NR2-ab in prediction of survival were 54.5% (95%CI=32.7%-74.9%), 100% (95%CI=84.5%-100%), infinite, and 
45.5% (95%CI=28.8%-71.8%), respectively. Subsequent analysis showed that both NR2-ab status and GCS were 
independent risk factors of death. Conclusions: A positive NR2-ab serum test 1 hour after ROSC correlated with 
lower 72-hour survival. Further studies are required to validate this finding and demonstrate the value of a quan-
titative NR2-ab assay and its optimal time of measurement. 
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Introduction: 
eurological recovery is the ultimate goal of suc-
cessful cardiopulmonary resuscitation (CPR) (1). 
However, early post-CPR neurological assess-
ment is a clinical challenge (1). Transient cerebral ische-
mia, sedative medications, and hypothermic resuscita-
tion are common factors that interfere with early post-
CPR neurological assessment (2, 3). Furthermore, there 
are insufficient data to support the reliability of ad-
vanced imaging techniques, including computed tomog-
raphy (CT) and magnetic resonance imaging (MRI), for 
detection of early ischemic changes, even if they can fea-
sibly be performed in unstable post-CPR patients (2, 4).  
Recently, serum biomarkers have received growing at-
tention for their ability to indicate neuronal ischemic 
damage. The greatest number of studies have been per-
formed on S100 and Neuron Specific Enolase (NSE) (5-
7), and both have failed to show a consistent correlation 
with post-CPR outcome in multiple studies. No bi-
omarkers have been shown to be useful in the few hours 
after cardiopulmonary arrest (5). Furthermore, increase 
in serum levels of these biomarkers are not specific to 
brain tissue injuries, making them questionable as ideal 
biomarkers (6). 
There is good evidence that the autoantibody toward N-
methyl-D-aspartate receptor subunits (NR2) peptide can 
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serve as an early sensitive neurotoxicity biomarker in is-
chemic stroke patients (8). The NR2 peptide is a subcom-
ponent of the N-methyl-D-aspartate receptor (NMDAR) 
and is ubiquitously distributed in the central nervous 
system (9-11). It has been shown that NMDAR is cleaved 
after blood-brain barrier rupture by means of different 
enzymes, including tissue plasminogen activator (t-PA), 
resulting in NR2B peptide release and prompting of an 
ultra-rapid antibody response (12, 13). NR2 antibody 
(NR2-ab) has been recognised as a neuronal ischemic bi-
omarker. It is useful for differentiation of ischemic 
strokes from intra-cranial haemorrhages within the first 
few hours after the event. It also identifies a subgroup of 
patients with acute transient ischemic attacks (TIA) who 
are at a higher risk for clinical complications (13, 14). 
When measured in patients who underwent cardiopul-
monary bypass for cardiac surgeries, serum NR2-ab was 
predictive of neurological complications (15). Addition-
ally, data from animal models have shown increased lev-
els of NR1, NR2A and, especially NR2B fragments in 
brain tissues after successful CPR has been performed on 
animals undergoing asphyxic cardiac arrest (16). Based 
on the above-mentioned points, we primarily raised the 
question of whether serum NR2-ab could predict poor 
outcome in successfully resuscitated patients. 
Methods: 
Study design and setting 
This prospective diagnostic test study was conducted in 
the emergency departments of two teaching hospitals in 
Tehran, Iran, with the annual census around 45000 and 
35000 patients, respectively. As a commitment to follow 
the under mentioned strict inclusion and exclusion crite-
ria, nonprobability convenience sampling was used to  
recruit the cases in shifts covered by selected authors 
who served as attending physicians during November, 
2011 to December, 2012. The protocol of this study was 
approved by Ethical Review Board of Iran University of 
Medical Sciences. Written consent was received from 
close family members of all participants. The code of eth-
ics of the World Medical Association (Declaration of Hel-
sinki, as revised in Seoul 2008) was fully read and fol-
lowed in the present work. 
Participants  
Those successfully resuscitated to the point of return of 
spontaneous circulation (ROSC) were considered eligi-
ble for the study, if they maintained that condition for at 
least one uninterrupted hour. Patients with age < 18 
years, traumatic or asphyxic arrest, head trauma within 
the past month, pregnant, or a history of disabling disor-
ders, end stage diseases, loss of blood specimen, central 
nervous system diseases,  persistent severe hypoxemia 
(O2 saturation < 88%) for at least 10 minutes, or re-
quired additional CPR attempts within the first hour af-
ter ROSC were excluded.  
 
Measurements 
A 5 ml sample of non-heparinised blood was drawn from 
a peripheral vein access 1 hour after ROSC. We followed 
the scientific literature and manufacturer instructions 
for the semi-quantitative enzyme-linked immuno-
sorbent assay (ELISA) kit for autoantibodies toward the 
NR2B fragment of the NMDA receptor (Human Gluta-
mate (NMDA) Receptor Subunit Epsilon-2 Antibody 
(NR2B-ab) ELISA Kit, CUSABIO, China). Briefly, blood 
samples were centrifuged within 10 min of collection at 
3000 cycles/min for 10 min, and the serum was moved 
and stored at -20 C° immediately. Thereafter, the sam-
ples were assessed using ELISA kits up to two months af-
ter the blood sampling date (13). An available micro-
plate reader (Micro Reader 4 Plus, Hyperion, USA) was 
used to read the ELISA plates. Resuscitation efforts were 
started either by emergency medicine service personnel 
or immediately after arrival at emergency department 
by the emergency department staff, who had been 
trained to follow the 2010 American Heart Association 
Guidelines for Cardiopulmonary Resuscitation and 
Emergency Cardiovascular Care Science as the standard 
of care for cardiopulmonary arrest. 
Data collection 
Demographic data, medical history regarding hyperten-
sion (HTN), diabetes, and hyperlipidemia and smoking 
background were later collected from several sources, 
including the patients, if possible, close family members 
and available medical documents. Using a structured 
checklist, trained emergency medicine residents were 
responsible for gathering data on the time interval be-
tween cardiac arrest and CPR initiation, CPR duration, 
number of CPR attempts after the first hour of the ROSC, 
GCS, blood pressure, duration of hospitalization, survival 
outcome at 1, 6, 24, and 72 hours after ROSC, and neuro-
logical and functional outcome of the patients at the time 
of hospital discharge. 
Statistical analysis 
PASW 18.0 software (IBM SPSS Statistics, IBM Co., New 
York, United States) was used to perform all of the sta-
tistical analyses. Chi square and Mann-Whitney U tests 
were applied to compare the categorical and continuous 
data, respectively. Screening performance characteris-
tics of NR2B-ab in prediction of 72-hour survival were 
calculated. All the reported values were two-sided. To 
account for the multiple testing effect in the comparison 
analyses of the baseline characteristics between the sur-
vived and non-survived groups, a p < 0.01 was consid-
ered significant. Using the Wald test, variables with sig-
nificant statistical and clinical differences were selected 
for the Cox proportional hazards model, in which p < 
0.05 was considered significant. The Mann-Whitney U 
test was employed to compare the GCS scores between 
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Results: 
49 successfully resuscitated patients were evaluated; 27   
(55%) survived to hospital discharge, 4 (8.1%) were in 
vegetative state, 10 (20.4) were physically disabled, and 
13 (26.5%) were physically functional. The baseline 
characteristics of the patients are shown in Table 1. Sen-
sitivity, specificity, positive and negative predictive val-
ues, and positive and negative likelihood ratios of NR2-
ab in prediction of survival were 54.5% (95% CI=32.7-
74.9), 100% (95% CI = 84.5-100), 100% (95% CI = 69.9-
100), 73% (95% CI = 55.6-85.6), infinite, and 45.5% 
(95% CI=28.8-71.8), respectively. 
Survival analyses 
Within 72 hours of ROSC all of the 12 NR2-ab positive 
patients died. In contrast, 31 (84%) of the NR2-ab nega-
tive patients survived, and 27 of them survived to hospi-
tal discharge after 1 to 47 days hospitalization (Table 2). 
There were significant differences in mean arterial pres-
sure (MAP) 1 hour after ROSC, NR2-ab, and GCS of survi-
vors and non-survivors (Table 1). We omitted MAP in the 
Cox proportional hazards model because the 10 mmHg 
mean difference was not clinically significant. The subse-
quent analysis showed that both NR2-ab status and GCS 
were independent risk factors for death (Table 3). Addi-
tionally, we found a clinically and statistically significant 
difference between the GCS scores in the NR2 subgroups, 
at 1, 6 and 24 hours after ROSC (Table 4). 
Discussion: 
Based on the results of this study, there was a significant 
correlation between the positive results of serum NR2-
ab 1 hour after ROSC and 72-hour survival of patients 
with successful CPR. Additionally, in the NR2-ab positive 
patients, GCS was significantly lower 1, 6, and 24 hours 
after ROSC, indicating a correlation between the bi-
omarker and negative outcome even before all the pa-
tients with positive tests had died. Our results are in 
agreement with a multitude of studies that focused on 
the association of this ischemic neuronal biomarker with 
the extent of neuronal damage and clinical outcome, par-
ticularly for ischemic stroke and TIA patients (8, 13, 17). 
We propose that the underlying pathophysiology of 
brain ischemia in cardiopulmonary arrest, which is 
global cerebral hypo perfusion, is similar to the local 
hypo perfusion observed in TIA and CVA patients. Thus, 
the mechanism of rise in the serum NR2 antibody level 
in post-CPR patients could be the same as that in TIA and 
CVA patients (16). In addition to the prognostic impact 
of NR2-ab, we observed that lower MAP and GCS 1 hour 
after ROSC also were indicative of poor survival out-
come. The 10-mmHg difference between mean MAP val-
ues of the two groups was not considered clinically sig-
nificant. Therefore, we disregarded the MAP values 
when generating the Cox proportional hazard model. We 
found that each was an independent prognostic factor 
for survival. Our data are in line with the idea of a more 
extensive approach toward factor inclusion in prognos-
tic models. In our case, this meant the incorporation of 
both GCS score and serum biomarkers to create a more 
potent prognostic tool (18). Nevertheless, the wide-
spread practice of sedating patients after resuscitation 
and the increasing application of therapeutic hypother-
mia in recent years affects the prognostic value of the 
GCS score (19), further highlighting the importance of al-
ternative prognostic tools such as NR2-ab. An interesting 
finding of our study was the high specificity of serum 
NR2-ab level 1 hour after ROSC in prediction of survival. 
To the best of our knowledge, all other time-specific bi-
omarker studies for post-CPR prognostication have used 







Number 22 (44.9) 27 (55.1)  
Male gender 10 (45.5) 14 (51.9) 0.66 
Age (range) 56.5 (19-75) 53.0 (22-73) 0.94 
Diabetes 7 (31.8) 5 (18.5) 0.28 
Hypertension 9 (40.9) 11 (40.7) 0.99 
Hyperlipidemia 10 (45.5) 5 (18.5) 0.04 
Smoking 9 (40.9) 7 (25.9) 0.27 
Arrest to CPR (minute) 10 (0-20) 10 (0-80) 0.35 
CPR duration (minute) 32.5 (2-75) 20 (5-70) 0.18 
Repeated CPR after 1 hour ROSC 10 (45.5) 4 (14.8) 0.02 
Arrest to blood sampling (minute) 100 (62-150) 90 (65-210) 0.19 
NR2-ab positive 1 hour after ROSC** 12 (54.5) 0 (0) <0.001 
GCS# score  at 1 hour after ROSC 3 (3-5) 7 (3-15) <0.001 
MAP## at 1 hour after ROSC (mmHg) 69.2 (65-83) 80 (67-117) <0.001 
*Mann-Whitney U test and Chi square test were applied where appropriate, **ROSC: return of spontaneous circu-
lation, # GCS: Glasgow coma scale, ##MAP: mean arterial pressure. 
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a longer time interval for blood sampling. The few stud-
ies on NR2-ab, which were conducted in other areas (e.g., 
TIA and CVA), chose longer intervals for blood sampling 
(a minimum of 3 hour after the event) (13). We postulate 
that the NR2 antibody level will increase in the few hours 
following an event. That means gaining more survival 
prediction sensitivity if sampling is repeated later. It re-
mains to be determined whether later measurement of 
NR2-ab will have sufficient sensitivity to predict neuro-
logical outcome in survivors of cardiopulmonary arrest. 
The ultra-rapid antibody response to NR2 antigen re-
mains a matter of debate. Because of the widespread ex-
pression of the NMDA receptor in the brain and the cer-
ebral endothelial barrier, it is probable that antigenic 
sensitisation to the NMDA receptor occurs through mi-
nor neurological incidences, such as trivial head trauma 
over a person’s lifetime. In this way, an anamnestic re-
sponse to subsequent antigenic exposures, which occurs 
immediately after brain injury, can explain the rapidness 
of the antibody response. This hypothesis is in accord-
ance with the observation that, in acute stroke patients, 
the serum NR2-ab level distinguishes between patients 
with or without prior brain ischemic events (17). Ubiq-
uitous and exclusive expression of the NMDA receptor 
throughout the CNS results in spatial accuracy. Moreo-
ver, the rapid appearance of both NMDA receptor frag-
ments and antibodies denotes temporal sensitivity for 
the NR2 peptide and antibody. Spatio-temporal proper-
ties of the NR2-ab may define it as an ideal biomarker in 
cases of ischemic neuronal injury (6, 20). Our finding, 
that a positive serum NR2-ab within 1 hour after ROSC 
was an independent prognostic factor of survival, sup-
ports this theoretical consideration. There are potential 
wider clinical applications for this test in the future. Car-
bon monoxide poisoning, shock, near-drowning and hy-
pothermia are good examples. Those conditions have 
one thing in common: the extent of hypoxic neurologic 
damage is the main determinant of prognosis. 
Limitations: 
There were several limitations to our study. First, 
nonprobability convenience sampling and a relatively 
low number of patients were recruited, mainly because 
of highly selective inclusion criteria. Second, relying on a 
semi-quantitative kit to detect abnormal NR2-ab levels. 
Third, we did not measure the serum NR2-ab level seri-
ally. Indeed, 45% (N=10) of those who eventually died in 
their time at the hospital were NR2-ab negative. This 
suggests that those patients may have had positive test 
results if it had been repeated later. This is similar to the 
higher “cumulative sensitivity” that results from the se-
Table 2: Cumulative survival rates for resuscitated patients based on serum NR2-ab (antibody) status 1 hour 
after successful resuscitation  
Antibody Outcome 
Time, n (%) 
Total 
 6 hours 24 hours 72 hours 7 Days 14 Days 30 Days 
Negative          
 
Died  2 (20) 6 (60) 6 (60) 9 (90) 10 (100) --- 10 (27) 
Survived  0 (0) 1 (4) 3 (11) 5 (19)  16 (60) 26 (96) 27 (73) 
Positive          
 
Died  1 (8) 8 (67) 12 (100) --- --- --- 12 (100) 
Survived  --- --- --- --- --- --- 0 (0) 
 
Table 3: Cox regression model of NR2 antibody status and Glasgow coma scale (GCS) 1 hour after return of 
spontaneous circulation  
 Hazard Ratio (95% CI) P-value* 
NR2 antibody unadjusted 8.33 (3.02-23.01) <0.001 
NR2 antibody adjusted for GCS score 3.41 (1.25-9.25) 0.02 
GCS score unadjusted 0.306 (0.11-0.84) 0.02 
GCS score adjusted for NR2 antibody 0.35 (0.13-0.94) 0.04 
*Wald test is applied. 
 
Table 4: Comparison of Glasgow coma scale (GCS) in different times after successful resuscitation based on se-
rum NR2 antibody status 
GCS NR2-ab  positive* NR2-ab  negative* Mann-Whitney U P-value 
1 hour after ROSC** 3 (3-3; 3-5) 5 (3-12; 3-15) 100.50 0.002 
6 hour after ROSC 3 (3-3; 3-5) 8 (5-13; 3-15) 50.50 <0.001 
24 hour after ROSC 3.00 11 (8-15; 3-15) 1.50 0.006 
72 hour after ROSC --- 11.5 (9-15; 3-15) --- --- 
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rial measurement of Troponin in cases of myocardial in-
farction (21). Fourth, because of funding limitations, we 
did not assess the NR2 peptide level simultaneously. It is 
unclear how this co-measurement could have improved 
the test characteristics. Fifth, we applied GCS as a meas-
urement tool for neurological assessment. Although GCS 
was originally employed to predict outcome of patients 
with traumatic brain injury, it is of value to describe the 
level of consciousness in non-trauma patients. Specifi-
cally, it has been used to evaluate the outcome of suc-
cessfully resuscitated patients (18). 
Conclusion: 
The status of serum NR2-ab level, 1 hour after ROSC, may 
be a predictor of short-term survival in successfully re-
suscitated patients. Further studies are required to 
demonstrate whether serial quantitative measurements 
of serum NR2-ab or a simultaneous measurement of the 
serum NR2 peptide provides additional prognostication 
value. 
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